Hemicentral Retinal Vein Occlusion: Causes and Treatment
Understanding Hemicentral Retinal Vein Occlusion
The retina is the thin layer of tissue at the back of the eye that senses light and sends visual signals to the brain. Blood flows into the retina through arteries and drains out through veins. In most people, a single central retinal vein carries blood away from the retina. However, some people are born with a variant where this vein splits into two trunks inside the optic nerve. One trunk serves the upper half and one serves the lower half of the retina.
When one of these two trunks becomes blocked, it is called a hemicentral retinal vein occlusion. The blockage causes blood to back up in the affected half of the retina. This leads to swelling, hemorrhages (bleeding), and fluid leakage. First described in 1980, hemi-CRVO is now recognized as a distinct condition. It is separate from both central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
Hemi-CRVO shares many features with CRVO because both involve blockages of the central retinal vein system. The key difference is that hemi-CRVO affects only one half of the retina, while CRVO affects the entire retina. In a study of 1,108 patients with retinal vein occlusions, 154 patients (13.9%) had hemicentral retinal vein occlusion (Hayreh et al., 1994).
Branch retinal vein occlusion (BRVO) also affects part of the retina, but it occurs where an artery crosses over and compresses a vein. Hemi-CRVO does not involve this type of arteriovenous crossing. Instead, the blockage happens within or near the optic nerve head. This distinction matters because it affects how the condition is managed.
Hemi-CRVO can present in two forms. The non-ischemic form, sometimes called venous stasis retinopathy, is the milder type. Blood flow is slowed but not severely reduced. Vision loss may be moderate, and the outlook is generally better.
The ischemic form, also called hemorrhagic retinopathy, involves more severe blockage. This form cuts off blood supply to retinal tissue. It carries a higher risk of complications, including the growth of abnormal new blood vessels. A retina specialist will determine which form is present through careful examination and testing.
When one trunk of the central retinal vein is blocked, blood cannot drain properly from the affected half of the retina. This raises pressure inside the small blood vessels. The vessels then leak fluid and blood into the surrounding retinal tissue. The retina responds by producing higher levels of vascular endothelial growth factor (VEGF), a protein that signals the body to grow new blood vessels.
While VEGF serves a normal role in the body, excessive VEGF in the eye causes problems. It makes existing blood vessels more leaky, worsening macular edema (swelling at the center of the retina). It can also trigger the growth of fragile, abnormal blood vessels prone to bleeding. These vessels can grow on the retina, the optic disc, or the iris. Growth on the iris can cause a serious condition called neovascular glaucoma.
Who Is Affected and Risk Factors
Hemi-CRVO most commonly affects adults over age 50, with the large majority of cases occurring in this age group (Hayreh et al., 1994). However, it can occur in younger individuals as well. A smaller proportion of patients are younger than 45 years (Hayreh et al., 1994). Younger patients who develop this condition may have different underlying causes, including blood clotting disorders or inflammatory conditions.
Several health conditions increase the risk of developing hemi-CRVO. Identifying and managing these risk factors is an important part of care.
- High blood pressure is the strongest modifiable risk factor. People with hypertension face a significantly elevated risk of retinal vein occlusion.
- Diabetes mellitus contributes to blood vessel damage throughout the body, including the retinal veins.
- High cholesterol and cardiovascular disease promote atherosclerosis (hardening of the arteries), which can affect nearby veins.
- Hypercoagulable states, which are conditions that cause blood to clot more easily, increase the chance of vein blockage.
Certain eye conditions are also linked to hemi-CRVO. The prevalence of glaucoma in patients with hemicentral retinal vein occlusion is 9.9%, and ocular hypertension (elevated eye pressure without glaucoma damage) is 16.2% (Hayreh et al., 2004). Both rates are significantly higher than in the general population. In the Ocular Hypertension Treatment Study, 7 of 26 retinal vein occlusions over 10 years were hemicentral cases, representing 26.9% of all vein occlusions in that group (OHTS, 2009).
The essential prerequisite for hemi-CRVO is the congenital anatomical variant in which the central retinal vein has two trunks. Without this variant, the condition cannot occur. Some people are anatomically predisposed to hemi-CRVO from birth. However, most do not develop it unless additional risk factors are present.
When hemi-CRVO occurs in patients under age 40, a retina specialist may recommend a thorough evaluation for underlying conditions. This may include blood tests for clotting disorders such as Factor V Leiden, antiphospholipid syndrome, or protein C and S deficiencies. Inflammatory conditions that affect blood vessels or the optic nerve may also be investigated.
Signs and Symptoms
The hallmark symptom of hemi-CRVO is sudden, painless vision changes. Because the condition affects only the upper or lower half of the retina, symptoms may involve a specific area of the visual field. If the superior (upper) retinal veins are blocked, the lower visual field is affected. If the inferior (lower) veins are blocked, the upper visual field is affected.
Many patients notice blurred or distorted central vision if fluid accumulates at the macula. The macula is the part of the retina responsible for sharp, detailed sight. Some patients describe a dark area or shadow in part of their vision.
Certain symptoms demand urgent evaluation by a retina specialist or an emergency room visit. Early treatment within the first month after symptom onset significantly improves outcomes.
- Sudden loss of vision in one eye, affecting the upper or lower half of the visual field
- Blurred or distorted central vision that develops rapidly
- New floaters, which may indicate bleeding inside the eye from abnormal blood vessels
- Eye pain combined with redness, which could suggest neovascular glaucoma
In some cases, the initial symptoms are mild, and patients may not seek care right away. Over weeks to months, macular edema can worsen, causing progressively blurred central vision. If abnormal blood vessels grow, they may bleed into the vitreous (the gel-like substance filling the eye). This can cause a sudden increase in floaters or a significant drop in vision. Regular monitoring helps catch these changes before they cause lasting damage.
Diagnosis and Testing
A retina specialist will begin with a dilated eye exam using special lenses to examine the retina in detail. In hemi-CRVO, the characteristic findings include flame-shaped hemorrhages (areas of bleeding), dilated and tortuous veins, and possibly cotton-wool spots. These signs are confined to either the upper or lower half of the retina. The other half appears normal, distinguishing hemi-CRVO from full CRVO.
Optical coherence tomography (OCT) is a noninvasive imaging test that creates detailed cross-sectional images of the retina. It is essential for detecting and measuring macular edema. OCT allows a retina specialist to see fluid buildup within or beneath the retinal layers with high precision. This test is used at every follow-up visit to guide treatment decisions.
Fluorescein angiography involves injecting a safe, yellow-orange dye into a vein in the arm. As the dye circulates through the retinal blood vessels, a special camera captures images. This test reveals areas of blocked blood flow, leaking vessels, and any abnormal new blood vessel growth. It is particularly useful for distinguishing between the non-ischemic and ischemic forms of hemi-CRVO.
Because hemi-CRVO is associated with systemic health conditions, a retina specialist may recommend blood pressure measurement, blood sugar testing, and cholesterol panels. For younger patients or those without typical risk factors, blood tests for clotting disorders may also be ordered. Coordination with a primary care physician is often an important part of the overall management plan.
Treatment Options
The primary treatment for macular edema caused by hemi-CRVO is intravitreal anti-VEGF therapy. These are injections of medication directly into the vitreous cavity of the eye. Anti-VEGF agents work by blocking vascular endothelial growth factor, the protein responsible for abnormal blood vessel growth and fluid leakage.
Treatment typically begins with a loading phase of three monthly injections, followed by ongoing treatment based on the eye's response. The schedule may follow a treat-and-extend approach, where the interval between injections is gradually lengthened. Alternatively, a pro re nata (as needed) approach gives injections only when swelling returns.
Several anti-VEGF medications are used for treating retinal vein occlusions. Each has different properties and dosing schedules.
- Eylea (aflibercept) is FDA-approved for macular edema following retinal vein occlusion. It is typically given every four to eight weeks after the initial loading phase.
- Eylea HD (high-dose aflibercept) offers extended dosing intervals, potentially every 8 to 16 weeks after the loading phase.
- Lucentis (ranibizumab) was one of the first anti-VEGF agents approved for retinal vein occlusion. It is typically given every four weeks.
- Avastin (bevacizumab) is FDA-approved for cancer treatment and is used off-label for eye conditions, including retinal vein occlusion. It is given every four to six weeks.
- Vabysmo (faricimab) is a bispecific antibody that targets both VEGF-A and angiopoietin-2. It offers potential for extended treatment intervals of every 4 to 16 weeks.
For patients who do not respond well to anti-VEGF therapy, intravitreal corticosteroids may be used. Ozurdex (dexamethasone implant) is a small, biodegradable implant placed inside the eye. It slowly releases medication over several months, reducing inflammation and fluid leakage. Corticosteroids can raise eye pressure and increase the risk of cataract formation, so careful monitoring is required.
Panretinal photocoagulation (PRP), a type of laser treatment, may be needed if abnormal new blood vessels develop. Laser treatment works by sealing off areas of damaged retina. This reduces the overall demand for oxygen and decreases the stimulus for abnormal vessel growth. It does not improve central vision directly but helps prevent serious complications like neovascular glaucoma and vitreous hemorrhage.
Managing the systemic conditions that contributed to hemi-CRVO is a critical part of treatment. Controlling blood pressure, blood sugar, and cholesterol reduces the risk of the condition worsening or affecting the other eye. A retina specialist may work closely with a primary care physician or cardiologist to coordinate this care.
What to Expect
The timing of treatment has a significant impact on visual outcomes. With early intervention and appropriate anti-VEGF treatment, many patients achieve meaningful visual improvement. However, results vary based on the severity of the occlusion, whether the ischemic or non-ischemic form is present, and how quickly treatment begins.
Patients should expect frequent visits during the first six months. Monthly monitoring is essential during this period to detect complications early. After the initial loading phase of three anti-VEGF injections, the treatment schedule is adjusted based on OCT results. Some patients achieve stable vision with gradually decreasing injection frequency. Others require ongoing treatment for months or years.
Even after vision stabilizes, regular follow-up remains important. The ischemic form of hemi-CRVO carries a risk of neovascularization (abnormal blood vessel growth). This can lead to vitreous hemorrhage or neovascular glaucoma. A retina specialist will continue to monitor for these complications through dilated exams and imaging. Any new symptoms, such as increased floaters, eye pain, or sudden vision changes, should be reported promptly.
Living With Hemicentral Retinal Vein Occlusion
Depending on the severity of hemi-CRVO and the response to treatment, some patients experience lasting changes to their vision. Central vision may remain somewhat blurred if macular edema caused long-term retinal changes. Part of the peripheral visual field may also be reduced. Low-vision aids such as magnifying devices, large-print materials, and improved lighting can help with daily tasks.
After a hemi-CRVO diagnosis, taking active steps to protect overall eye and vascular health becomes especially important.
- Keep blood pressure within the target range recommended by your primary care physician.
- Manage diabetes carefully with regular blood sugar monitoring and appropriate medication.
- Attend all scheduled follow-up appointments with your retina specialist, even when vision feels stable.
- Report any new visual symptoms to your retina specialist without delay.
A sudden change in vision can be stressful and disorienting. Many patients benefit from connecting with support groups for people with vision loss or retinal conditions. Occupational therapists who specialize in low vision can provide practical strategies for maintaining independence. Open communication with your retina specialist about concerns and treatment goals is an important part of long-term care.
When to See a Retina Specialist
See a retina specialist or go to the emergency room immediately if you experience sudden vision loss in one eye, a new shadow or curtain blocking part of your vision, a sudden increase in floaters, or flashes of light. These symptoms could indicate hemi-CRVO, retinal detachment, or other sight-threatening conditions. Early treatment provides the best chance of preserving vision.
If you have been diagnosed with hemi-CRVO, follow the monitoring schedule recommended by your retina specialist. Contact your specialist between appointments if you notice worsening of vision, new floaters, or eye pain with redness. Patients with risk factors such as high blood pressure, diabetes, or glaucoma should have regular dilated eye exams. Early detection of vein occlusion improves treatment outcomes.
Questions and Answers
Hemi-CRVO typically affects one eye at a time. However, because the underlying risk factors affect the entire body, a vein occlusion could occur in the other eye in the future. This is one reason why managing systemic health conditions is so important after a diagnosis. Your retina specialist will monitor both eyes during follow-up visits.
The duration of treatment varies from person to person. Some patients achieve stable vision after several months of injections and can gradually extend the time between treatments. Others require injections for a year or longer to keep macular edema under control. Your retina specialist will use OCT imaging at each visit to determine when it is safe to adjust the treatment schedule.
Visual recovery depends on several factors. These include the severity of the occlusion, whether it is the ischemic or non-ischemic form, and how quickly treatment was started. Many patients experience meaningful improvement with treatment. However, some degree of lasting change is possible, especially if macular edema persisted for a prolonged period. Early diagnosis and consistent treatment offer the best opportunity for visual recovery.
Some people refer to retinal vein occlusions informally as an 'eye stroke.' While the comparison captures the idea of a blocked blood vessel, the conditions are not identical. In hemi-CRVO, a vein is blocked, causing blood to back up in the retina. In a true stroke, an artery is typically blocked, cutting off blood supply to part of the brain. Having a retinal vein occlusion can indicate increased cardiovascular risk. A thorough evaluation of heart and blood vessel health is often recommended.
Having a central retinal vein that splits into two trunks is a congenital anatomical variant present in a certain proportion of the population. Most people with this variant do not develop hemi-CRVO. The condition only occurs when additional risk factors cause a clot to form in one of the trunks. Maintaining good cardiovascular health and having regular eye exams are the best ways to reduce risk.